




FEDERATED LEARNING IN PHARMA: TURNING POSSIBILITIES INTO PRACTICE



As federated learning (FL) gains traction in the pharmaceutical domain, the focus is shifting from theoretical potential to practical implementation. Pharma companies are increasingly seeking ways to leverage FL to enable secure collaboration, derive insights from real-world data, and accelerate innovation—without compromising patient privacy or data ownership. What follows is an exploration of real-world use cases, industry case studies, and strategic considerations that illustrates how organizations can potentially operationalize FL as part of their broader data strategy.



Unlocking Value: Where Federated Learning Meets Pharma Innovation

While the applications of Federated Learning (FL) in the pharmaceutical landscape are vast, the examples below highlight key areas where it is already making a measurable impact.

Use Cases

Collaborative Drug Discovery

Objective:
Accelerate drug discovery by securely sharing insights across pharmaceutical companies while protecting proprietary data

Impact:
Enables pharma organizations to train AI models to predict drug-target interactions, identify potential drug candidates, optimize molecular structures etc

Enhanced Clinical Trial Recruitment

Objective:
Improve patient recruitment and site selection for clinical trials by securely analyzing decentralized patient data

Impact:
Shortens clinical trial recruitment timeline by enabling AI models to analyze distributed EHR across providers while complying with HIPAA/GDPR

Real-World Evidence (RWE) Generation

Objective:
Enable secure, large-scale data analysis for post-market drug surveillance and regulatory decision-making.

Impact:
Decentralized patient data can be aggregated and analyzed to evaluate drug efficacy, support regulatory submissions, monitor adverse events etc.

Cross-Company Pharmacovigilance

Objective:
Improve detection of adverse drug reactions (ADRs) through secure collaboration among pharmaceutical companies.

Impact:
This allows organizations to jointly train AI models on decentralized pharmacovigilance data, enhancing the identification of ADR patterns without sharing sensitive data.

Synthetic Data Generation for AI Training

Objective:
Create high-quality synthetic datasets for AI model development without exposing real patient data.

Impact:
Preserves privacy while enabling scalable AI development.

FL-Driven Must Stock List (MSL) Optimization

Objective:
Optimize medicine stocking across pharmacies, hospitals, and distributors while protecting sales data.

Impact:
Improve demand forecasting, reduce stockouts, and enhance supply chain efficiency without sharing sensitive data.


Proof on the Ground: Case Studies from the Pharma Frontlines

FL is still emerging; these case studies showcase how leading organizations are already translating its promise into tangible outcomes.

	MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery)	Owkin	MedPerf (FL Benchmarking Framework)
Objective	Train predictive models for drug discovery using proprietary pharma data.	Connect hospitals to train AI models on decentralized patient data.	Benchmark clinical AI models on decentralized datasets
Approach	Built a secure FL platform across 10 pharma companies and research institutes.	Deployed FL to preserve hospital data sovereignty.	Combined FL with governance protocols to evaluate model efficacy.
Outcomes	Trained on 2.6B data points; enabled collaborative R&D while safeguarding IP.	Improved model generalization reduced legal and privacy barriers.	Used in the large-scale FeTS 2.0 study; adopted by global oncology consortia.


The Next Phase: Ecosystem Readiness and Technology Convergence

The future lies in cross-industry FL ecosystems, interoperable platforms, and privacy-first tech — making secure collaboration the new normal.



Blueprint to Scale: A Strategic Roadmap for FL Implementation

A clear, step-by-step path to move from pilots to enterprise-scale FL, aligning leadership, governance, compliance, and infrastructure.



Toward a Privacy-Driven, Collaborative Future in Pharma

To Conclude, operationalizing federated learning in pharma is no longer a distant goal. Early-stage implementations show strong promise, particularly in areas like drug discovery, clinical trial design, and post-market surveillance. As adoption scales, strategic enablers such as cross-industry partnerships, data governance maturity, and interoperable FL platforms will determine success. The path forward lies in aligning privacy-first innovation with regulatory expectations—creating an ecosystem where data collaboration accelerates discovery, strengthens compliance, and improves outcomes across the healthcare value chain.



Authors



Saarthak Gupta

Senior Consultant, ICLS, Infosys Consulting

Saarthak is a Senior Consultant in Infosys Consulting's Life Sciences practice within the LS Data Transformation Team with more than 7 years of professional experience. He has experience in Life Sciences, Healthcare, Information Technology and Ed-Tech industries. He has worked in multiple engagements on Data Analytics, Data Migration and Transformation, Data Quality Management, Reference Data Management, Net Revenue Management and AI Implementation.



Pragnya Koya

Consultant, ICLS, Infosys Consulting

Pragnya is a Business Consulting professional with 4+ years of experience in the Healthcare and Life Sciences sectors. She brings a robust blend of expertise in product development, performance reporting and improvement, and customer experience enhancement, consistently leveraging strong data management and analytical skills to drive tangible results.



Nitisha Nitin Patil

Analyst, ICLS, Infosys Consulting

Nitisha is an experienced Analyst with a strong background in the Healthcare and Life Sciences industries. She brings expertise in stakeholder management, data analysis, and business process understanding. Her proficiency spans stakeholder engagement, requirement analysis, data interpretation, and cross-functional collaboration to deliver impactful business solutions.



Ramya Gunza

Principal, ICLS, Infosys Consulting

Ramya is a seasoned Principal Business Consultant with around 10 years of experience within the Healthcare and Life Sciences industries, possessing deep expertise in data management, data quality, business intelligence and AI. Her proficiency extends to Data Office initiatives, Commercial Excellence strategies, and delivery of impactful data-driven solutions.

ABOUT INFOSYS CONSULTING:

Infosys Consulting is a next-generation consulting partner that bridges strategy and execution. With an AI-first mindset, deep industry knowledge, and the combined strengths of business and technology consulting, it helps enterprises turn bold vision into tangible outcomes, faster, smarter, and at scale.

Infosys Consulting is helping some of the world's most recognizable brands transform and innovate. Our consultants are industry experts that lead complex change agendas driven by disruptive technology. With offices in 20 countries and backed by the power of the global Infosys brand, our teams help the C-suite navigate today's digital landscape to win market share and create shareholder value for lasting competitive advantage.

CONNECT WITH US

